JP2020524149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524149A5 JP2020524149A5 JP2019569878A JP2019569878A JP2020524149A5 JP 2020524149 A5 JP2020524149 A5 JP 2020524149A5 JP 2019569878 A JP2019569878 A JP 2019569878A JP 2019569878 A JP2019569878 A JP 2019569878A JP 2020524149 A5 JP2020524149 A5 JP 2020524149A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- treg
- breg
- cancer
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 78
- 239000003795 chemical substances by application Substances 0.000 claims description 63
- 206010028980 Neoplasm Diseases 0.000 claims description 62
- 201000011510 cancer Diseases 0.000 claims description 56
- 239000012634 fragment Substances 0.000 claims description 52
- 239000003446 ligand Substances 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 41
- 239000002955 immunomodulating agent Substances 0.000 claims description 36
- 210000003289 regulatory T cell Anatomy 0.000 claims description 35
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims description 32
- 239000003112 inhibitor Substances 0.000 claims description 30
- 230000037361 pathway Effects 0.000 claims description 30
- 108700002109 Transmembrane Activator and CAML Interactor Proteins 0.000 claims description 28
- 102000050862 Transmembrane Activator and CAML Interactor Human genes 0.000 claims description 28
- 239000012190 activator Substances 0.000 claims description 28
- 239000000427 antigen Substances 0.000 claims description 28
- 108091007433 antigens Proteins 0.000 claims description 28
- 102000036639 antigens Human genes 0.000 claims description 28
- 238000000423 cell based assay Methods 0.000 claims description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 239000004055 small Interfering RNA Substances 0.000 claims description 24
- 230000002401 inhibitory effect Effects 0.000 claims description 21
- 230000005965 immune activity Effects 0.000 claims description 20
- 230000003993 interaction Effects 0.000 claims description 17
- 108020005004 Guide RNA Proteins 0.000 claims description 16
- 108090000174 Interleukin-10 Proteins 0.000 claims description 16
- 102000003814 Interleukin-10 Human genes 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 230000004083 survival effect Effects 0.000 claims description 16
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 14
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 12
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims description 12
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims description 12
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 12
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 12
- -1 ICOS Proteins 0.000 claims description 12
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims description 12
- 229940127089 cytotoxic agent Drugs 0.000 claims description 12
- 230000002519 immonomodulatory effect Effects 0.000 claims description 12
- 230000002452 interceptive effect Effects 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 12
- 238000010171 animal model Methods 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 102100025584 Leukocyte immunoglobulin-like receptor subfamily B member 1 Human genes 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 8
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 claims description 8
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 claims description 8
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims description 8
- 101150104237 Birc3 gene Proteins 0.000 claims description 8
- 108091033409 CRISPR Proteins 0.000 claims description 8
- 108091079001 CRISPR RNA Proteins 0.000 claims description 8
- 238000010354 CRISPR gene editing Methods 0.000 claims description 8
- 108010058546 Cyclin D1 Proteins 0.000 claims description 8
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 claims description 8
- 102100024185 G1/S-specific cyclin-D2 Human genes 0.000 claims description 8
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 8
- 101000980741 Homo sapiens G1/S-specific cyclin-D2 Proteins 0.000 claims description 8
- 108700011259 MicroRNAs Proteins 0.000 claims description 8
- 108091007412 Piwi-interacting RNA Proteins 0.000 claims description 8
- 101100379220 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) API2 gene Proteins 0.000 claims description 8
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 8
- 108020004459 Small interfering RNA Proteins 0.000 claims description 8
- MXZACTZQSGYANA-UHFFFAOYSA-N chembl545463 Chemical compound Cl.C1=CC(OC)=CC=C1C(N=C1)=CN2C1=NC(C)=C2O MXZACTZQSGYANA-UHFFFAOYSA-N 0.000 claims description 8
- 239000002254 cytotoxic agent Substances 0.000 claims description 8
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000012636 effector Substances 0.000 claims description 8
- 239000002679 microRNA Substances 0.000 claims description 8
- CYAJEMFRSQGFIG-ISWIILBPSA-N microcystin-LA Natural products CO[C@@H](Cc1ccccc1)[C@@H](C)C=C(C)C=C[C@H](NC(=O)CNC(=O)[C@@H](C)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)NC(=O)C(=C)N(C)C(=O)CC[C@@H](C)C(=O)O)C(=O)O)[C@H](C)C(=O)N CYAJEMFRSQGFIG-ISWIILBPSA-N 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 230000001575 pathological effect Effects 0.000 claims description 7
- JPSHPWJJSVEEAX-OWPBQMJCSA-N (2s)-2-amino-4-fluoranylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC([18F])C(O)=O JPSHPWJJSVEEAX-OWPBQMJCSA-N 0.000 claims description 6
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 6
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 6
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 6
- 101150051188 Adora2a gene Proteins 0.000 claims description 6
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 6
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 6
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 6
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 6
- 102100024263 CD160 antigen Human genes 0.000 claims description 6
- 102100038078 CD276 antigen Human genes 0.000 claims description 6
- 102100036008 CD48 antigen Human genes 0.000 claims description 6
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 6
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 6
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 6
- 102100035943 HERV-H LTR-associating protein 2 Human genes 0.000 claims description 6
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 claims description 6
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 6
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 6
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 6
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 6
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 6
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 6
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 6
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 6
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 claims description 6
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 6
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 claims description 6
- 101000984190 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 1 Proteins 0.000 claims description 6
- 101000984189 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 2 Proteins 0.000 claims description 6
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 6
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 6
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 6
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 6
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 6
- 102100034980 ICOS ligand Human genes 0.000 claims description 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 6
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 6
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 6
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 claims description 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 6
- 102000002698 KIR Receptors Human genes 0.000 claims description 6
- 108010043610 KIR Receptors Proteins 0.000 claims description 6
- 102000017578 LAG3 Human genes 0.000 claims description 6
- 101150030213 Lag3 gene Proteins 0.000 claims description 6
- 102100025583 Leukocyte immunoglobulin-like receptor subfamily B member 2 Human genes 0.000 claims description 6
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 6
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 6
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 6
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 claims description 6
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 6
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 6
- 101150036449 SIRPA gene Proteins 0.000 claims description 6
- 229940044665 STING agonist Drugs 0.000 claims description 6
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 6
- 102100039367 T-cell immunoglobulin and mucin domain-containing protein 4 Human genes 0.000 claims description 6
- 101710174757 T-cell immunoglobulin and mucin domain-containing protein 4 Proteins 0.000 claims description 6
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 6
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 6
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 6
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 6
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 6
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 229940022399 cancer vaccine Drugs 0.000 claims description 6
- 238000009566 cancer vaccine Methods 0.000 claims description 6
- 230000016396 cytokine production Effects 0.000 claims description 6
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 208000010362 Protozoan Infections Diseases 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 230000009286 beneficial effect Effects 0.000 claims description 5
- 230000004064 dysfunction Effects 0.000 claims description 5
- 206010014881 enterobiasis Diseases 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 230000001506 immunosuppresive effect Effects 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 238000010172 mouse model Methods 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 108091023037 Aptamer Proteins 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 4
- 239000003124 biologic agent Substances 0.000 claims description 4
- 239000003131 biological toxin Substances 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 4
- 239000012830 cancer therapeutic Substances 0.000 claims description 4
- 230000002222 downregulating effect Effects 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 150000003384 small molecules Chemical group 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 108700012359 toxins Proteins 0.000 claims description 4
- 230000007170 pathology Effects 0.000 claims description 3
- 210000002707 regulatory b cell Anatomy 0.000 claims description 3
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 claims description 2
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 230000036961 partial effect Effects 0.000 claims description 2
- 230000004043 responsiveness Effects 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 230000003827 upregulation Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 18
- 241000699666 Mus <mouse, genus> Species 0.000 claims 7
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 101710145805 Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 2
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 230000009471 action Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762522167P | 2017-06-20 | 2017-06-20 | |
| US62/522,167 | 2017-06-20 | ||
| US201762573264P | 2017-10-17 | 2017-10-17 | |
| US62/573,264 | 2017-10-17 | ||
| US201862677265P | 2018-05-29 | 2018-05-29 | |
| US62/677,265 | 2018-05-29 | ||
| PCT/US2018/038490 WO2018236995A2 (en) | 2017-06-20 | 2018-06-20 | Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020524149A JP2020524149A (ja) | 2020-08-13 |
| JP2020524149A5 true JP2020524149A5 (enExample) | 2021-07-29 |
Family
ID=64735842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569878A Pending JP2020524149A (ja) | 2017-06-20 | 2018-06-20 | Ａｐｒｉｌ−ｔａｃｉ間相互作用のモジュレーターを用いた制御性ｔ細胞、制御性ｂ細胞、及び免疫応答の調節方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12005073B2 (enExample) |
| EP (1) | EP3642243A4 (enExample) |
| JP (1) | JP2020524149A (enExample) |
| CN (1) | CN110945030A (enExample) |
| AU (1) | AU2018289493B2 (enExample) |
| CA (1) | CA3064632A1 (enExample) |
| WO (1) | WO2018236995A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110192106B (zh) * | 2017-01-16 | 2021-09-28 | 株式会社岛津制作所 | 数据解析装置以及数据解析用程序 |
| CA3064632A1 (en) | 2017-06-20 | 2018-12-27 | Dana-Farber Cancer Institute, Inc. | Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction |
| MA56057A (fr) * | 2019-05-31 | 2022-04-06 | Dana Farber Cancer Inst Inc | Polythérapie |
| TW202208414A (zh) | 2020-05-08 | 2022-03-01 | 美商艾爾潘免疫科學有限公司 | April及baff抑制性免疫調節蛋白及其使用方法 |
| WO2022048314A1 (zh) * | 2020-09-03 | 2022-03-10 | 上海易慕峰生物科技有限公司 | 针对循环肿瘤细胞的免疫杀伤细胞在实体瘤治疗中的应用 |
| CN113368262A (zh) * | 2020-09-03 | 2021-09-10 | 上海易慕峰生物科技有限公司 | 通过实体肿瘤转移动物模型获取中间结果的方法 |
| JP2023549023A (ja) * | 2020-09-29 | 2023-11-22 | パーデュー・リサーチ・ファウンデーション | クルクソンジテルペノイドおよびその使用法 |
| CN113278619B (zh) * | 2021-07-19 | 2021-10-15 | 广东省农业科学院动物科学研究所 | 双sgRNA、基因敲除载体、基因敲除STING基因的猪成纤维细胞系及其构建方法 |
| CN114147343B (zh) * | 2021-12-08 | 2024-08-16 | 西安中科微精光子科技股份有限公司 | 一种激光加工方法、系统及计算机存储介质 |
| CN118126196B (zh) * | 2024-03-06 | 2024-08-16 | 中国医学科学院基础医学研究所 | 一种具有包含taci融合蛋白的基因工程化外泌体及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE361318T1 (de) | 2000-05-12 | 2007-05-15 | Amgen Inc | Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen |
| CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
| CN101323643B (zh) * | 2007-06-15 | 2010-12-01 | 烟台荣昌生物工程有限公司 | 优化的TACI-Fc融合蛋白 |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| US20120201823A1 (en) * | 2009-10-14 | 2012-08-09 | Schering Corporation | April antagonists and methods of use |
| CN102585016B (zh) | 2012-03-06 | 2014-06-04 | 江苏健德生物药业有限公司 | 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用 |
| NL2014108B1 (en) * | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| CA3064632A1 (en) | 2017-06-20 | 2018-12-27 | Dana-Farber Cancer Institute, Inc. | Methods for modulating regulatory t cells, regulatory b cells, and immune responses using modulators of the april-taci interaction |
-
2018
- 2018-06-20 CA CA3064632A patent/CA3064632A1/en active Pending
- 2018-06-20 EP EP18820336.8A patent/EP3642243A4/en active Pending
- 2018-06-20 US US16/612,938 patent/US12005073B2/en active Active
- 2018-06-20 AU AU2018289493A patent/AU2018289493B2/en active Active
- 2018-06-20 CN CN201880048338.0A patent/CN110945030A/zh active Pending
- 2018-06-20 WO PCT/US2018/038490 patent/WO2018236995A2/en not_active Ceased
- 2018-06-20 JP JP2019569878A patent/JP2020524149A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524149A5 (enExample) | ||
| AU2023203601B2 (en) | Ex vivo bite-activated T cells | |
| Stein et al. | Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation | |
| CN104427992B (zh) | 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法 | |
| JP2022513685A (ja) | 養子細胞療法を用いた処置のための方法 | |
| US20220169694A1 (en) | Chimeric antigen receptor t cell therapy | |
| JP2021521137A (ja) | 腫瘍微小環境の特性を使用するキメラ受容体ｔ細胞治療 | |
| JP2021524240A (ja) | 二重特異性抗体の組成物及びその使用方法 | |
| JP2016509582A5 (enExample) | ||
| US20240110230A1 (en) | Biomarkers for cancer treatment | |
| US20250313855A1 (en) | Chimeric antigen receptor t cell therapy | |
| CN114206346A (zh) | 施用嵌合抗原受体免疫疗法的方法 | |
| CA3160479A1 (en) | Lag-3 antagonist therapy for melanoma | |
| Rajagopal et al. | Immune‐related adverse events of antibody‐based biological medicines in cancer therapy | |
| Chew et al. | Effects of brief adjunctive metformin therapy in virologically suppressed HIV-infected adults on polyfunctional HIV-specific CD8 T cell responses to PD-L1 blockade | |
| US20210252036A1 (en) | Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k) | |
| CN117412987A (zh) | 用于癌症治疗的cd274突变 | |
| US20240252633A1 (en) | Methods of treating cancer with cd-40 agonists | |
| US20240158869A1 (en) | Factors for optimizing immunotherapy | |
| Stock et al. | Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma | |
| US20250290154A1 (en) | Predictive markers for immunotherapy | |
| US20250161361A1 (en) | Factors for optimizing immunotherapy efficacy | |
| Gross et al. | CD19× CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease | |
| Miyahira et al. | The 29th Annual Prostate Cancer Foundation Scientific Retreat Report | |
| CN119546638A (zh) | 用于cd19靶向的car t细胞的二线疗法的治疗方法 |